Comparative Pharmacology
Head-to-head clinical analysis: ARALEN versus MALARONE PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARALEN versus MALARONE PEDIATRIC.
ARALEN vs MALARONE PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
MALARONE PEDIATRIC is a fixed-dose combination of atovaquone and proguanil. Atovaquone selectively inhibits the mitochondrial electron transport chain of Plasmodium species at the cytochrome bc1 complex, collapsing mitochondrial membrane potential and disrupting pyrimidine synthesis. Proguanil is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase in the parasite, blocking DNA synthesis. The combination synergistically kills blood-stage schizonts and inhibits liver-stage hypnozoites of P. falciparum.
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
Adults: 250 mg atovaquone/100 mg proguanil orally once daily for 3 consecutive days for treatment; for prophylaxis, 250 mg/100 mg orally once daily starting 1-2 days before travel and continued for 7 days after leaving endemic area.
None Documented
None Documented
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Atovaquone: terminal half-life 1.5-3 days (range 2-3 days in adults, longer in children). Proguanil: terminal half-life 12-21 hours (parent drug) and 14-23 hours (cycloguanil). Clinically, atovaquone's long half-life supports single daily dosing.
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
Atovaquone: >90% excreted unchanged in feces via biliary elimination; <1% renal. Proguanil: ~40-60% excreted renally as unchanged drug and active metabolite cycloguanil; ~30% fecal.
Category C
Category C
Antimalarial
Antimalarial